Luminex xMAP technology
The Luminex xMAP technology is a bead-based, multiplex immunoassay platform designed for simultaneous detection of multiple analytes in a single sample, with the capacity to identify up to 500 different targets. This method, applied in both protein and DNA detection, is rapid, cost-effective, and capable of high-throughput analysis, and IVD assays.
In a Luminex xMAP assay for protein detection, beads with distinct spectral addresses (color-coded) are conjugated to an antibody (or antigen) that specifically recognizes a protein of interest and then incubated with the sample. Following washing steps to clear non- specific binders, a mixture of protein-specific biotinylated antibodies is added to allow for specific formation of a complex (sandwich). Signal detection is performed by addition of a streptavidin-phycoerythrin reagent which binds to the biotinylated secondary antibodies and emits light upon excitation by a laser beam in the Luminex instrumentation. A separate laser is used to distinguish the different bead regions resulting in the acquisition of multiple readings per sample each representing the signal from the binding to a different protein.
Advantages of Luminex
Luminex technology is a versatile and powerful platform offering numerous advantages for both clinical diagnostics and research applications. Luminex offers flexibility with custom panels, high throughput, and low sample volume requirements. Also Luminex xMAP has excellent repeatability in a cost-effective way.
Clinically, Luminex is used for disease diagnosis, monitoring treatment responses,
and prognosis, while in research, it supports biomarker discovery, validation, and understanding disease mechanisms. Its capacity to work with small sample volumes, often as little as 10 μl,is particularly advantageous when dealing with limited or precious specimens.
One of the main advantage of Luminex technology compared to other multiplex competitors are its applicability for IVD (in vitro diagnostics) since all the 3 instruments (MagPix, LX200, and FlexMAP) have the regulatory specifications required to be used in a clinical and diagnostic lab
The platform’s high sensitivity, with a detection limit of few pg/ml, ensures the accurate detection of even low-abundance biomarkers, making it suitable for early disease detection and precise quantitative analyses. Additionally, the wide linearity range allows for accurate quantification across a broad spectrum of concentrations. Even though xMAP technology can multiplex up to 500 analytes in a single test, most protein applications limit the use for up to 100 analytes in order to be compatible across instruments (LX200, and FlexMAP3D) as well as to limit the effect of antibody cross reactivity.
Luminex also demonstrates excellent repeatability, providing reliable and consistent results, which are crucial in both clinical diagnostics and research. Its rapid processing speed, capable of tens of thousands of readouts per hour, enhances laboratory efficiency and allows for quick turnaround times, making it an essential tool for time-sensitive environments. Overall, Luminex’s combination of high performance and cost-effectiveness makes it an attractive option for laboratories and institutions looking for efficient, scalable solutions.
Applications
Luminex harnesses the proven xMAP® Technology to drive innovation in scientific development, facilitating breakthroughs in both applied and basic research. Luminex xMAP technology’s ability to multiplex and provide high-throughput analysis makes it a valuable tool in various fields of research and clinical practice. Here are some of the applications:
Diagnostics Applications
Luminex xMAP technology plays a vital role in diagnostics across various fields. In transplantation, it helps monitor immune responses and detect potential transplant rejection. For autoimmune diseases, it identifies and analyzes autoantibodies, aiding in accurate diagnosis. In oncology, it profiles cancer biomarkers to assist in diagnosis, personalized treatment selection, and prognosis. Additionally, it is used for allergy testing, allowing for the simultaneous detection of multiple allergens to diagnose allergic conditions efficiently
Applied technologies
Luminex xMAP technology is used in microbiome research and clinical diagnosis to analyze microbial communities and their impact on health. Also in the food industry and in food testing helps in detecting pathogens and contaminants, ensuring in this way the safety and quality of the products.
BioPharma
In the BioPharma field, Luminex xMAP technology supports drug discovery and promotes drug and vaccine development by enabling high-throughput screening, immunogenicity assessment, anti-drug antibody characterization and bioanalysis in PD studies. It is used to study mechanisms of action, identify secreted proteins, and perform immune profiling, accelerating research and development processes.
Public health
In public health, Luminex xMAP technology is crucial for disease surveillance, enabling the detection and monitoring of pathogens and pathogen-specific antibodies across populations. This helps track outbreaks, assess the spread of diseases, monitor seroprevalence and support public health responses to emerging health threats.
Academic research
In academic research, Luminex xMAP technology is essential for the detection of secreted proteins, enabling researchers to explore cellular communication and function. It is also used to investigate the mechanism of action of various biological processes and treatments, offering insights into how they affect cells.
Luminex xMAP services by Protavio
At Protavio, our mission of advancing proteomics for better health drives our commitment to pioneering protein research. This commitment is reflected in our multi-year partnership with Luminex to offer custom services on the xMAP platform.
Assay development
Our assay development (C-Plex) service leverages the power of Luminex™ xMAP technology to develop fully customizable protein assays tailored to your research or clinical needs. Whether you are interested in immunoassays, serology, or other types of assays, C-Plex allows you to select specific protein targets and sample types. We handle the rest, from development to delivery, ensuring you receive a reagent kit ready for use in your lab or receive high quality data with our mid-plex protein analysis service.
ISO13485 development and GMP production for clinical use
Protavio offers a complete solution for the development and manufacturing of custom Luminex assays for clinical use. This service encompasses the design, development, production, and commercialization support for your novel biomarker discoveries, enabling their use in clinical practice either as IVD (In Vitro Diagnostics), or LDT (Laboratory Developed Test) assays. Our development and production process ensures compliance with In Vitro Diagnostic Regulations (IVDR), ISO13485 standards, and GMP guaranteeing the quality, safety, and efficacy of your clinical diagnostic products.
By integrating Luminex xMAP technology into our suite of services, we provide the scientific community with comprehensive solutions for diagnostic assay development.
Protavio is proud to be a Luminex partner, emphasizing our dedication to excellence and our commitment to providing essential tools and insights for advancing proteomics and biomarker discovery.
Why Protavio?
20+ years of multiplex proteomics experience
GMP, ISO:9001, ISO:13485 compliant processes
Advanced bioinformatic analysis for proteomics
Orthogonal biomarker validation with multiple platforms
The Team
Leonidas Alexopoulos
PhD, Acting CEO, Professor, National Technical University of Athens
Leonidas is one of the pioneers of multiplex assays & systems biology with more than 20 years of experience in the field of proteomics. He has studied at Duke, MIT and Harvard and is currently a professor at National Technical University of Athens. Leonidas co-founded Protavio in 2011 with the ultimate goal of improving people’s health through innovation in proteomics.
Sophia Stamatatou
Co-founder, COO & Quality Director, MSc, MBA
Sophia holds an MSc in Robotics & Automation and an MBA from National Technical University of Athens. Her passion for engineering and entrepreneurship led her to co-found Protavio in 2011. Since 2018, she has held the position of Chief Operating Officer and Quality Director. Her decade long experience of business development and administration make her a key decision maker in Protavio.
Nikos Tsolakos
Chief Scientific Officer, Phd
Nikos holds a PhD from Imperial College London and has over 15 years of work experience in academic and industrial research positions in the field of proteomics. Nikos joined Protavio in 2017 as a Quality Assurance & Project Manager. Since 2023, he holds the position of Chief Scientific Officer to advance Protavio’s proteomic solutions.
Christos Fotis
Chief Innovation Officer, Phd
Christos holds a PhD in AI & Bioinformatics from National Technical University of Athens and has extensive experience in creating and managing R&D projects and consortia. Christos joined Protavio in 2021 as a Research & Innovation manager. Since 2023, he holds the position of Chief Innovation Officer to drive new innovative projects using proteomics.